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Abstract
Background: Most older adults live with multiple chronic disease conditions, yet the effect of multiple diseases on brain function remains
unclear.
Methods: We examine the relationship between disease multimorbidity and brain activity using regional cerebral blood flow (rCBF)
15
O-water PET scans from 97 cognitively normal participants (mean baseline age 76.5) in the Baltimore Longitudinal Study of Aging (BLSA).
Multimorbidity index scores, generated from the presence of 13 health conditions, were correlated with PET data at baseline and in longitudinal
change (n = 74) over 5.05 (2.74 SD) years.
Results: At baseline, voxel-based analysis showed that higher multimorbidity scores were associated with lower relative activity in orbitofrontal,
superior frontal, temporal pole and parahippocampal regions, and greater activity in lateral temporal, occipital, and cerebellar regions.
Examination of the individual health conditions comprising the index score showed hypertension and chronic kidney disease individually
contributed to the overall multimorbidity pattern of altered activity. Longitudinally, both increases and decreases in activity were seen in
relation to increasing multimorbidity over time. These associations were identified in orbitofrontal, lateral temporal, brainstem, and cerebellar
areas.
Conclusion: Together, these results show that greater multimorbidity is associated with widespread areas of altered brain activity, supporting
a link between health and changes in aging brain function.
Keywords: Brain activity, Health, Imaging, MRI, PET

Age is a primary risk factor for a myriad of health-related medical
conditions (1). In fact, it is estimated that up to 80% of people in the
United States over the age of 65 have more than one serious medical
condition (2). Of those individuals, 23% have conditions significant
enough to be considered in poor health, meaning that illness impacts
activities of daily living and often results in an overall lower quality
of life (3). Age is also the primary risk factor for cognitive decline
and dementia (4,5), highlighting a link between health status and the
development of cognitive impairment in older individuals.
Over the past several years, studies have investigated the link between the number of medical conditions an individual has, known as
multimorbidity, and the development and progression of dementia.
These studies have shown that multimorbidity is a predictor for
mild cognitive impairment (MCI) (6,7) or the prodromal stage of

Alzheimer’s disease (AD), and that health factors most associated
with MCI are hypertension and other vascular-related conditions
(7,8). Further studies have shown that multimorbidity is associated
with progression from MCI to AD (9), with greater multimorbidity
linked to more rapid cognitive decline and progression of dementia severity (10,11). On a more practical level, physicians, and
especially geriatricians, often report that patients with substantial
multimorbidity frequently develop cognitive problems, and that effective treatment of non-neurological health conditions tends to improve cognitive function. However, this observation has not been
fully investigated and the mechanisms that connect brain health with
multimorbidity remain unclear.
Although few have investigated the impact of multimorbidity
on the brain, two studies point to a link between multimorbidity
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Method
Participants
The BLSA is a study of natural human aging established in 1958
and conducted by the National Institute on Aging (NIA) Intramural
Research Program. The BLSA continuously enrolls healthy volunteers aged 20 years and older who are followed for life to assess
changes in health and functional status (17). We used data from 97
cognitively normal older participants (>50 years of age at baseline;
50 males; mean age 76.5 (7.8 SD)) from the neuroimaging substudy
of the BLSA who had concurrent assessment of multimorbidity and
15
O-water rCBF PET scan collected on a GE Advance scanner at
baseline (Table 1). Of these 97 participants, 74 had annual concurrent multimorbidity and longitudinal PET assessments collected over
a period of 5.05 (2.74) years. None of the individuals in this study
had a clinical diagnosis of mild cognitive impairment or dementia
throughout the study interval. The individuals were also free of significant health conditions that could affect brain function (ie, clinical stroke with brain tissue loss or displacement, closed head injury,
brain surgery, malignant cancer, meningiomas and cysts with brain
tissue displacement, seizure, and bipolar disorders).
This study was approved by the local Institutional Review
Boards. All participants provided written informed consent prior to
each assessment.

Table 1. Participant Demographics
Participants (n)

97

Males, n (%)
Age (years)
Scan Interval (mean years [SD]; n = 75)
Baseline MMSE (mean years [SD])
Baseline Multimorbidity Index Score (mean [SD])
Baseline Multimorbidity Index Range
Last Visit Multimorbidity Index Score (mean [SD])
Last Visit Multimorbidity Index Range

50 (51.5%)
76.5 (7.8)
5.05 (2.74)
29.1 (1.0)
2.86 (1.63)
0–7
3.24 (1.79)
0–7

Note: Mini-mental State Exam (MMSE) score out of a possible 30.
Multimorbidity Index represents the average number of disease conditions.

Multimorbidity Index
The multimorbidity index was defined at the baseline visit (ie, first
concurrent assessment of multimorbidity and 15O-water PET) and at
each longitudinal assessment. It was defined as the number of diagnosed conditions from a predefined list of 13 conditions. These conditions were chosen based on the high prevalence and high risk of
disability in older adults, the availability of adjudicated data in the
BLSA database, and the use of these conditions in previous studies
of BLSA participants (18,19). Hypertension, diabetes, ischemic heart
disease, congestive heart failure, COPD, cancer, Parkinson’s disease,
hip fracture, and lower extremity joint disease were defined using
standard criteria that combined information from self-reported
medical history, medication use, medical documents, and a clinical
medical examination. Anemia was defined as hemoglobin <12 g/dL
in women and <13 g/dL in men; CKD was defined as glomerular filtration rate estimated using the Cockroft–Gault equation <30 mL/L,
and peripheral arterial disease was defined as ankle-brachial index
measured by Doppler stethoscope <0.9. Subclinical stroke was defined by a medical history of a TIA without evidence on magnetic
resonance imaging (MRI).
Participants were also administered the Center for
Epidemiological Studies-Depression scale (CES-D; (20) to assess depressive symptoms, but the CES-D was not included in the calculation of the multimorbidity index score.

PET Imaging
Annual resting-state cerebral blood flow (CBF) scans were acquired
on a GE Advance PET scanner in 3-dimensional mode (image
matrix = 128 × 128, 35 slices, voxel size = 2 × 2 mm, slice thickness = 4.25 mm) and reconstructed with a filtered back projection
after a 10 mCi injection of 15O-water. Images were obtained for
60 seconds once the total radioactivity counts in the brain reached
threshold levels. A transmission scan in 2-dimensional mode using a
68
Ge rotating source was applied for attenuation correction. Using
Statistical Parametric Mapping (SPM12 Wellcome Department of
Cognitive Neurology, London, England), the PET scans were spatially normalized into standard stereotaxic space and smoothed
using a gaussian kernel to a full width at half maximum of 10, 10,
and 10 mm in the x, y, and z planes, respectively. To control for variability in global flow, rCBF at each voxel was ratio-adjusted to the
mean global flow and scaled to 50 mL/100 g/min for each image.

PET Imaging Analysis
To examine the association between multimorbidity index score
and brain function, whole brain voxel-wise multiple regression analyses were performed using statistical parametric mapping (SPM12),
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and brain structure and function. Using a large sample of cognitively normal older participants from the Mayo Clinic Study
of Aging (MCSA), Vassilaki and colleagues (12) found that increased multimorbidity is associated with alterations in cortical
thickness and glucose metabolism in regions of known AD pathology. Data from the Dallas Heart Study also show older individuals with medical comorbidities have accelerated increases in
white matter (WM) hyperintensity volume with increasing age
(13). These findings suggest that multimorbidity may influence
brain structure and function, particularly in regions vulnerable to
neuropathologic changes in AD.
Whereas previous studies have examined brain structure or function within predefined regions, we examine the relationship between
multimorbidity and brain function in the Baltimore Longitudinal
Study of Aging (BLSA) using a whole brain voxel-level technique.
Annual resting-state 15O-water positron emission tomography (PET)
scans were used to assess regional cerebral blood flow (rCBF) as an
index of brain function (14). Brain activity measured by 15O-water
PET is based on the principle that local increases in neuronal activity
lead to co-localized regional increases in blood flow to meet the increased glucose and oxygen demand of the activated tissue (15). In
this way, rCBF is an indirect measure of localized neuronal activity.
In this study, we examined the cross-sectional and longitudinal relationships between multimorbidity and brain function in a
group of 97 cognitively normal older participants in the Baltimore
Longitudinal Study of Aging (BLSA). We generated multimorbidity
index scores based on the number of the following 13 conditions
each person exhibited: anemia, cancer, congestive heart failure,
chronic kidney disease (CKD), chronic obstructive pulmonary disease
(COPD), diabetes, hip fracture, heart ischemic disease, hypertension,
joint disease, Parkinson’s disease, peripheral artery disease, and subclinical stroke/transient ischemic attack (TIA) (16). The relationship
between multimorbidity score and baseline rCBF was examined, as
well as the relationship between change in multimorbidity score over
time and longitudinal change in rCBF.
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MRI Scanning
MRI structural images were acquired using either a GE Signa 1.5 T
or Philips Achieva 3 T scanner. A 3-D T1-weighted spoiled gradient

refocused (SPGR) MRI scan (TR = 35 ms TR, TE = 5 ms, 8° flip angle,
256 × 256 matrix, 0. 94 × 0.94 mm2 voxel size, 1.5 mm slice thickness, 124 slices) was collected on the GE scanner, and a MPRAGE T1
scan was collected on the Philips scanner (TR = 6.8 ms, TE = 3.2 ms,
8° flip angle, 256 × 256 matrix, 1 × 1 mm2 voxel size, 1.2 mm slice
thickness, and 170 sagittal slices). Eighty-three of the 97 participants
had MRI data available for use.

MRI GM and WM Volume Calculation
Volume data were extracted from RAVENS (Regional Analysis of
Volumes Examined in Normalized Space) maps (24). The intensity
values in a RAVENS map quantifies the regional distribution of GM,
WM, and cerebrospinal fluid (CSF), with one RAVENS map for each
tissue type. RAVENS values in the template space are directly proportional to the volume of the respective structures in the original
brain scan.
In BLSA, to achieve optimal consistency between regional
(volumetric) and voxel-wise analyses, we used a region of interest
(ROI)-based segmentation approach in the calculation of RAVENS
maps. To do this, anatomical ROIs were first segmented on the
T1-weighted scan of each participant using a method that combines the MUSE anatomical labeling approach (25) with harmonized acquisition-specific atlases (26). The tissue type of each ROI was
then used to segment the brain into GM, WM, and CSF. Also, to
make the RAVENS calculation more robust to registration errors,
we applied an “ensemble approach” by using 3 state-of-the-art deformable registration methods, DRAMMS (27), ANTS (28), and
DEMONS (29), for subject-to-template warping, and by averaging
RAVENS maps obtained using each method to compute the final
RAVENS values.
Binary maps of the clusters showing an association between
multimorbidity index score and CBF were generated from the PET
analysis, and total volumes of GM + WM were calculated within
each cluster for each participant. The clusters were corrected for
intracranial volume (ICV) tissue volume and scanner strength (1.5
vs 3T), then included as a covariate in the follow-up PET analyses.
In the baseline PET analysis, the ICV-corrected tissue volume for
each cluster was then included as a covariate in the follow-up PET
analyses. In the longitudinal PET analysis, the rate of change in MRI
volume of each cluster was included as a covariate in the follow-up
analyses.

Results
Multimorbidity
Participants had a mean multimorbidity index score of 2.86 (1.63
SD) and a range of 0–7 conditions at baseline (Supplementary Figure
1). These scores were similar to those observed in a larger sample of
BLSA participants (19). At baseline, hypertension (n = 69; 70%), joint
disease (n = 62; 64%), and CKD (n = 34; 35%) were the most prevalent conditions in the sample, followed by diabetes, anemia, cancer,
subclinical stroke, ischemic heart disease, and COPD. Hip fracture,
congestive heart failure, peripheral artery disease, and Parkinson’s
disease were the least prevalent conditions. At the last visit, participants had a mean multimorbidity index score of 3.24 (1.79 SD) and
a range of 0–7 conditions. Overall, 44 participants had unchanged
index scores over time, 18 participants increased by 1 condition, 10
participants increased by 2 conditions, and 2 participants increased by
3 conditions. Although only 30 of the 74 participants increased index
score over time, there was a significant difference between first and last
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controlling for baseline age and sex. Significant regions showing an
association between multimorbidity index score and rCBF were identified using a magnitude threshold of p ≤ .005, and a cluster size requirement of ≥50 contiguous voxels, as standardly used in BLSA PET
studies (21–23). To control for potential effects of brain volume on
rCBF, the analyses were repeated while controlling (covarying) for the
MRI gray matter (GM) and white matter (WM) volume of each cluster
observed in the PET analyses in a subsample who also had structural
data (n = 83). To control for the effects of depressive symptoms on differences in rCBF, the analysis was also repeated using the continuous
CES-D score as a covariate.
For each participant, the first available PET scan with a concurrent multimorbidity index score was used as the baseline scan.
For the baseline analysis, the baseline rCBF was regressed on the
baseline multimorbidity index scores, controlling for age and sex. To
determine if individual health conditions contributed to the overall
pattern related to multimorbidity, the conditions that make up the
multimorbidity index score were individually analyzed to assess the
contributions of each disease condition to the observed associations
seen in the baseline index score model. To ensure a proper fit of these
models, the analyses were limited to the 3 conditions with a prevalence >20% in the sample: hypertension, joint disease, and CKD.
In these analyses, a mask of baseline regions exhibiting associations
between index score and baseline rCBF was created. The effect of
each condition on rCBF was then examined separately by regressing
baseline rCBF on the individual condition scores, controlling for age
and sex, limited to voxels within the masked regions from the baseline analysis (p < .05, k = 50 voxels).
In the longitudinal analysis, change in rCBF was examined as
a function of change in multimorbidity score. For each participant
with longitudinal multimorbidity data available at each PET assessment (n = 74), a slope CBF image was created that quantified the rate
of change in CBF over time. For each voxel, a linear mixed effects
model (fixed effect of time, random effects of intercept and slope)
was implemented and the estimated random effects for slope were
extracted. Change in multimorbidity was determined by calculating
the difference between the first and last index score. The relationship
between change in multimorbidity and voxel-wise change in rCBF
and was then assessed using a multiple regression analysis, controlling for baseline age, sex, and longitudinal follow-up interval. To
control for potential effects of change in brain volume on change
in rCBF, the analyses were repeated while controlling for the rate
of change in GM and WM volume of each cluster observed in the
longitudinal PET analyses in a subsample who also had structural
data (n = 67). In follow-up analyses, individual health conditions
were assessed to determine contributions to the overall pattern related to increased multimorbidity. The conditions with the highest
prevalence in the sample (>20%) at last visit were again individually analyzed to assess the contributions of each disease condition to
the observed associations seen in the longitudinal change model. In
these analyses, a mask of longitudinal change in regions exhibiting
associations between change in index score and change in rCBF was
created. The effect of incidence of each medical condition at last visit
on changes in rCBF was then examined separately, limited to voxels
within the masked regions from the longitudinal analysis (p < .05,
k = 50 voxels).
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PET Imaging
Baseline associations
The baseline multimorbidity index scores showed both negative
and positive relationships with baseline rCBF (n = 97). Higher
multimorbidity index score was related to lower rCBF in the right
orbitofrontal cortex (Brodmann Area [BA] 11), superior frontal (BA
8, 10), and medial frontal cortices (BA 9). Higher multimorbidity
index score was also related to lower rCBF in the right temporal
pole (BA 38), and the left parahippocampal gyrus (BA 36). All regions remained significant when controlling for tissue volume of
each cluster with the exception of the parahippocampal gyrus.
These findings suggest that higher disease burden is related to lower
brain activity, as measured by lower rCBF, in frontal and temporal
brain regions.
Positive relationships, demonstrating higher rCBF in relation to
higher multimorbidity index scores, were observed in the right middle
temporal gyrus (BA 21), left inferior parietal cortex (BA 40), bilateral
cuneus (BA 18), and cerebellum (Figure 1, Table 2). All regions remained significant when controlling for tissue volume of each cluster
with the exception of the inferior parietal cortex. These findings suggest that higher disease burden also is associated with higher or preserved brain activity in posterior brain areas including temporal and
occipital cortices.
Neither negative nor positive relationships between
multimorbidity index score and rCBF changed when controlling for
depressive symptoms as a continuous score. Additionally, no main
effects of age or sex were observed in regions showing a relationship
between multimorbidity and rCBF.

Baseline contributions of individual disease components
To help understand if individual disease conditions contribute to
the overall patterns of rCBF differences seen with greater disease
burden, rCBF in significant regions at baseline was regressed on the
presence of specific disease conditions at baseline. The analyses were
limited to the conditions with the highest prevalence in the sample
(>20%). When examining hypertension (HTN), joint disease, and
CKD, HTN and CKD showed individual contributions to the altered patterns of blood flow. At baseline, both HTN and CKD were
related to with lower rCBF in superior frontal cortices (BA 10), with
CKD exhibiting additional associations with lower rCBF in temporal
pole (BA 38) and parahippocampal gyrus (BA 36) regions. HTN and
CKD were also related to with greater rCBF, with HTN associated
with greater rCBF in the middle temporal gyrus (BA 21) and cuneus
(BA 18), and CKD associated with greater rCBF in the cuneus (BA
18) and cerebellum (Figure 2, Table 3).
Longitudinal analysis
The longitudinal multimorbidity index scores showed mostly positive relationships with longitudinal change in rCBF (n = 74). Positive
relationships, demonstrating increased rCBF in relation to increased
multimorbidity index score, were observed in the left orbitofrontal
cortex (BA 11), right basal forebrain, left middle temporal gyrus (BA
21), right paracentral gyrus (BA 20), bilateral brainstem, and left
cerebellum (Figure 1, Table 2). Most regions remained significant
when controlling for change in tissue volume of each cluster over
time, except the basal forebrain region. This region was no longer
significant at p < .005 when controlling for change in tissue volume,
yet was observed at a lower threshold of p < .05. These findings suggest that increasing disease burden is associated with in increasing
brain activity in predominately anterior cortical areas including
frontal and temporal areas.
Increased multimorbidity index score was related to decreased
rCBF in the left middle temporal gyrus (BA 21). This region remained significant when controlling for change in tissue volume.
This finding suggests that increasing disease burden is related to relatively circumscribed decreases in brain activity over time.

Figure 1. Multimorbidity and brain function. Regions where higher multimorbidity scores correlated with levels of brain activity measured by rCBF (p < .005,
>50 voxels) are shown on sagittal slices beginning in the left and progressing through the right hemisphere. Regional patterns are shown at baseline and in
longitudinal change over time. Blue represents regions of lower baseline or decreased longitudinal activity; orange represents regions of higher or increased
activity.
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visit scores for the group (paired sample t-test, p < .001). Hypertension
(70%), joint disease (77%), and CKD (40%) were again the most
prevalent conditions at the last assessment. While hypertension remained unchanged, there was a 13% increase in joint disease, 7%
increase in subclinical stroke, and a 5% increase in COPD, CKD, and
anemia over the follow-up interval. Parkinson’s disease, congestive
heart failure, and ischemic heart disease increased by 2%, followed by
a 1% increase in diabetes.

1813

Journals of Gerontology: MEDICAL SCIENCES, 2022, Vol. 77, No. 9

1814

Table 2. Associations Between Multimorbidity and Brain Activity
MNI Coordinate
Region

x

y

z

Z score

p Value

voxels

R
L
R
L
R
R
R
L

6
−8
26
−28
12
22
38
−14

46
68
64
30
44
48
16
−10

−28
8
8
46
44
24
−32
−34

3.01
3.40
4.09
4.01
3.34
3.07
3.19
3.49

.001
<.001
<.001
<.001
<.001
.001
.001
<.001

60
95
175
381
51
80
315
121

R
B
L
L
R

52
0
−30
−46
4

−42
−100
−42
−68
−58

−8
10
46
−26
−32

3.38
4.40
3.31
3.37
3.10

<.001
<.001
.001
.001
<.001

143
974
50
160
109

L

−54

−22

0

3.79

L
R
L
R
B
L

−18
22
−52
14
2
−16

16
8
−32
−30
−26
−66

−18
−14
−6
50
−18
−14

3.66
3.73
5.16
4.64
3.55
3.09

161
<.001
<.001
<.001
<.001
<.001
.001

66
56
281
147
76
60

Note: Regions showing a relationship between multimorbidity score and brain activity measured by rCBF at baseline and change over time. The level of activity
in relation to increasing multimorbidity score is noted. Stereotaxic coordinates are listed; Brodmann areas (BA) are indicated in parentheses. *denotes regions that
did not survive tissue volume correction; **regions that did not survive tissue volume correction at p < .005, but were observed at p < .05.

Figure 2. Contributions of individual disease components at baseline. Of the 3 index components examined, hypertension and chronic kidney disease showed
individual contributions to the multimorbidity pattern observed at baseline. Significant regional correlations are circled in green. Lower brain activity is indicated
in blue, and higher activity in orange.
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Baseline Visit
Lower Activity
Orbitofrontal Cortex (11)
Superior Frontal Gyrus (10)
Superior Frontal Gyrus (10)
Superior Frontal Gyrus (8)
Superior Frontal Gyrus (8)
Medial Frontal Gyrus (9)
Temporal Pole (38)
Parahippocampal Gyrus (36)
Higher Activity
Middle Temporal Gyrus (21)
Cuneus (18)
Inferior Parietal Cortex (40)*
Cerebellum
Cerebellum
Longitudinal Change
Decreased Activity Over Time
Middle Temporal Gyrus (21)
Increased Activity Over Time
Orbitofrontal Cortex (11)
Basal Forebrain**
Middle Temporal Gyrus (21)
Paracentral Gyrus (20)
Brainstem
Cerebellum

Side
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Table 3. Individual Disease Components and Brain Activity
MNI Coordinate
Region

x

y

z

Z score

p value

Condition

L
R
L
R
L

−4
26
−24
34
−8

62
62
28
12
−2

22
12
44
−28
−26

3.29
2.88
2.94
4.03
3.09

<.001
.002
.002
<.001
.002

CKD
HTN
CKD
CKD
CKD

R
L
B
R
R

50
−6
−8
6
6

−42
−82
−100
−88
−52

−6
18
22
10
−32

3.49
2.60
3.28
2.11
3.07

<.001
.005
.001
.017
.001

HTN
HTN
CKD
CKD
CKD

Note: Regions where individual conditions contributed to the pattern of brain activity associated with multimorbidity score at baseline. Of the 3 index components examined, hypertension (HTN) and chronic kidney disease (CKD) showed individual contributions to the multimorbidity pattern observed at baseline.
Stereotaxic coordinates are listed; Brodmann areas are indicated in parentheses.

Longitudinal contributions of individual disease components
When examining HTN, joint disease, and CKD in relation to changes
in rCBF over time, no relationships were seen between increased incidence of these conditions and changes in rCBF. This is likely due to
minor increases in the incidence of the conditions over time (HTN
incidence unchanged; joint disease 13% increase; CKD 5% increase
over time).

Discussion
Using data from participants in the Baltimore Longitudinal study of
Aging, our results show that disease burden is associated with brain
function in older individuals. Greater disease burden was related to
both lower and higher relative brain activity as measured by rCBF.
At baseline, greater multimorbidity was associated with lower rCBF
in frontal and anterior temporal lobe regions, and with higher rCBF
in middle temporal, parietal and occipital areas of the brain. Over
time, increasing multimorbidity scores were related to decreased
rCBF in lateral temporal cortex and increased rCBF and frontal
and temporal lobe areas. These findings demonstrate that physical
health, often primarily associated with dysfunction of other organ
systems in the body, is associated with altered functional patterns in
the aging brain.
At baseline, participants in this sample had an average of 2.86
disease conditions, with a range of 0–7 conditions among the 13
used to construct the multimorbidity index score. Hypertension,
joint disease and CKD were the most prevalent conditions, followed
by diabetes, anemia, cancer, and subclinical stroke. At the last visit
approximately 5 years later, the multimorbidity index score increased
to an average of 3.24 disease conditions, with hypertension, joint
disease, and CKD remaining the most prevalent conditions. These
findings support other studies of disease prevalence in aging (30,31).
With regard to brain function, higher multimorbidity was associated with lower rCBF at baseline in the frontal lobes of the brain
including orbitofrontal and superior frontal regions. Other areas of
lower rCBF were seen in the temporal pole and parahippocampal
gyrus. Several regions also exhibited higher relative rCBF in relation
to higher multimorbidity index scores at baseline. Higher rCBF was
seen in lateral temporal, occipital, parietal, and cerebellar regions.
Longitudinally, we found decreased rCBF over time observed in the

middle temporal gyrus and increased rCBF observed in orbitofrontal,
basal forebrain, middle temporal, brainstem, and cerebellar regions
in relation to increasing multimorbidity scores over time. As some
of these longitudinal changes were observed in areas contralateral
to those seen at baseline, it is conceivable that these represent some
form of compensatory activity in response to the differences in baseline activity.
Together, these results show that greater multimorbidity is associated with widespread areas of lower brain activity, supporting
a link between health and decreases in aging brain function. As for
increased activity, increased brain activity in aging has historically
been interpreted as compensatory in nature, with the theory that
increased activity in some areas may compensate for decreased activity in others (32,33). More recent theories, however, suggest that
increased activity might also represent an excitotoxic reaction to
increasing neuropathology in aging (34,35), or represent a failure
to properly inhibit activity levels (36) with increasing age-related
neuropathologic burden. Alternately, higher relative rCBF in some
regions may reflect an attempt at preservation of function in view of
age-related declines in global cerebral blood flow.
Vascular issues related to disease states may also play a role in
the increased rCBF observed here. Health conditions can result in
compromised vascular autoregulation and neurovascular coupling
(37). While vascular dysregulation is typically presumed to result in
decreased cerebral blood flow, recent evidence suggests that there
are bidirectional effects on neuronal firing in the brain. Indeed,
Kim et al. (38) propose that there are “vasculo-neuronal” coupling effects that can lead to both decreased and increased neuronal
activity in relation to changes in vascular tone, with increased neuronal firing also occurring in response to decreased tissue perfusion.
Additionally, studies of hypertension (39), impaired insulin resistance (40), and anemia (41) have found increased brain activity in
relation to disease. Although it is difficult to define the underlying
causes of the observed associations, both higher and lower rCBF in
relation to greater disease burden indicate that poorer health results
in altered brain function in aging.
Because the multimorbidity index score represents a compilation of multiple health conditions, we also examined the role
of individual conditions in the overall pattern of compromised
rCBF. Of the most common health conditions occurring in this
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Baseline Associations
Lower Activity
Superior Frontal Gyrus (10)
Superior Frontal Gyrus (10)
Superior Frontal Gyrus (8)
Temporal Pole (38)
Parahippocampal Gyrus (36)
Higher Activity
Middle Temporal Gyrus (21)
Cuneus (18)
Cuneus (18)
Cuneus (18)
Cerebellum
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study. Finally, the follow-up interval for the longitudinal analysis
was relatively short and additional relationships may emerge over
longer intervals, and with a larger proportion of the sample exhibiting increased multimorbidity scores over time.
Together, our results show that multimorbidity affects brain function in older individuals, and that hypertension and CKD play individual roles in the altered patterns of activity. The decreased activity in
frontal and temporal lobe areas is particularly notable due to their role
in memory, planning, decision making, and emotion. Altered activity in
these areas raises the possibility of planning and decision making vulnerability with increased disease burden in the future, at a time when these
processes may be crucial for making proper health care decisions that
can greatly impact quality of life. It is also equally important to note that
many of the health conditions commonly observed in aging are modifiable with treatment and lifestyle changes, which may reduce the impact
of multimorbidity on the brain. Thus, maximizing health and preventing
multimorbidity should be a primary goal in the care and treatment of the
older population to preserve both physical and brain function.
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